DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) offers 2,320 bioactive compounds, each clinically approved by major regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA, or listed in recognized pharmacopeias (APExBIO). This library is optimized for high-throughput (HTS) and high-content screening (HCS) strategies, providing pre-dissolved 10 mM DMSO solutions in formats compatible with automated platforms. Key applications include drug repositioning, pharmacological target identification, and mechanism-of-action studies in oncology, neurodegeneration, and signal pathway research (Alexander-Howden et al., 2023). Stability is ensured for 12–24 months at prescribed storage temperatures. Standardization and traceability are guaranteed with 2D barcoded tubes and microplates, supporting reproducible screening campaigns.

Biological Rationale

Drug discovery increasingly leverages libraries of clinically approved compounds to accelerate translational research. FDA-approved compound libraries provide access to molecules with established safety and pharmacokinetic profiles, enabling rapid hypothesis testing and streamlined repurposing workflows (Alexander-Howden et al., 2023). Compounds targeting diverse mechanisms—such as receptor agonism/antagonism, enzyme inhibition, and ion channel modulation—are critical for probing complex signaling pathways in both health and disease. The DiscoveryProbe™ FDA-approved Drug Library is designed to support these research needs by providing a comprehensive, ready-to-screen collection of bioactives with defined regulatory status and known mechanisms of action. This approach reduces development risk and enhances the probability of identifying actionable hits suitable for further preclinical development.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds with well-documented mechanisms, including:

• Receptor agonists and antagonists: Targeting GPCRs, nuclear hormone receptors, and ion channels.
• Enzyme inhibitors: Inhibiting kinases, proteases, and metabolic enzymes, e.g., metformin (AMPK activator) and atorvastatin (HMG-CoA reductase inhibitor).
• Signal pathway regulators: Modulating MAPK, PI3K/AKT, and mTOR pathways.
• Ion channel modulators: Affecting neuronal excitability and cardiac function.

These compounds are selected based on regulatory approvals and comprehensive annotation of molecular targets and pathways. For example, in neurodevelopmental disease research, small molecules from approved libraries have been employed to disrupt protein–protein interactions such as MeCP2–TBL1/TBLR1, a validated target in MeCP2 duplication syndrome (MDS) (Alexander-Howden et al., 2023). Thus, the library supports a spectrum of screening modalities ranging from biochemical assays to complex cellular models.

Evidence & Benchmarks

• High-throughput screening (HTS) with FDA-approved compound libraries enables rapid identification of inhibitors for disease-relevant protein–protein interactions, with robust Z-factors (e.g., 0.85 in NanoLuc assays) (Alexander-Howden et al., 2023).
• Clinically approved drug collections facilitate drug repositioning by providing molecules with known safety and pharmacokinetic profiles, expediting translational research (https://doi.org/10.1038/s41598-023-29915-z).
• APExBIO's DiscoveryProbe™ FDA-approved Drug Library contains 2,320 unique compounds, each supplied as a 10 mM DMSO solution, stable for up to 24 months at -80°C (APExBIO product page).
• Included compounds address major pharmacological classes used in cancer, metabolic, neurodegenerative, and infectious disease research, supporting diverse biomedical applications (Internal: Antiviral screening applications).

For further application-specific context, see this article on advanced CYP3A4 modulation studies, which details mechanistic use cases for the DiscoveryProbe™ FDA-approved Drug Library. This article extends those findings by detailing regulatory provenance and benchmarking in high-content screening workflows.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is broadly applicable across basic and translational research domains:

• Drug repositioning screening for oncology and neurodegenerative targets.
• High-throughput screening (HTS) of pharmacological modulators in cell-based and biochemical assays (Related article; this article provides new benchmarks for target identification pipelines in neurodegeneration).
• High-content screening (HCS) for phenotypic profiling and pathway elucidation.
• Mechanistic validation of disease models, especially in cancer and rare genetic syndromes (Contrast: this article focuses on translational oncology; here, we address regulatory curation and stability).

Common Pitfalls or Misconceptions

• Not all compounds are suitable for in vivo use without additional formulation or toxicity assessment; the library is primarily intended for in vitro screening.
• Hits identified in HTS/HCS require further validation before clinical translation; initial activity does not guarantee efficacy in disease models.
• The presence of a compound in the FDA-approved list does not ensure activity against new or unrelated molecular targets.
• Compound stability is guaranteed only under recommended storage conditions (-20°C to -80°C; avoid repeated freeze-thaw cycles).
• Some regulatory approvals may have regional restrictions; always verify local regulatory guidance prior to translational application.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is provided as pre-dissolved 10 mM DMSO solutions, facilitating direct use in automated liquid handling platforms. Researchers may select between 96-well microplates, deep-well plates, or 2D-barcoded screw-top tubes. The compounds remain stable for 12 months at -20°C and up to 24 months at -80°C. Shipping can be requested at room temperature or on blue ice, with evaluation samples always shipped on ice. For high-throughput screening, recommended dispensing volumes range from 0.1 to 10 µL per assay, depending on the screening platform. The library supports integration with high-content imaging, biochemical assays, and phenotypic screens, enabling robust pharmacological profiling and rapid hit-to-lead assessment. APExBIO provides batch-level documentation and traceability for all compounds, supporting reproducible research and regulatory compliance.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) represents a rigorously curated, regulatory-grade resource for high-throughput and high-content drug discovery. With 2,320 clinically validated compounds, it enables efficient identification of novel therapeutic targets, supports rapid drug repositioning, and accelerates translational workflows in cancer, neurodegeneration, and rare disease research (product page). As demonstrated in recent peer-reviewed studies, such libraries are indispensable for the discovery of modulators of protein–protein interactions and pathway regulators (Alexander-Howden et al., 2023). By integrating robust annotation, flexible formats, and standardized quality controls, APExBIO’s DiscoveryProbe™ FDA-approved Drug Library continues to advance the frontiers of pharmacological research and screening innovation.